Combo Appears Effective After Anti-PD-1 Failure in Advanced Melanoma
Ipilimumab plus nivolumab demonstrated efficacy in a phase 2 trial of patients with advanced melanoma who failed prior anti-PD-1 therapy.
Ipilimumab plus nivolumab demonstrated efficacy in a phase 2 trial of patients with advanced melanoma who failed prior anti-PD-1 therapy.
Fixed-dose combination treatment with relatlimab plus nivolumab improved progression-free survival when compared with nivolumab alone.
Researchers compared the prognosis of patients with S-ITM and those with T3N0, T4N0, N1-N3, and M1 disease.
Results from a randomized trial neither support nor rule out the possibility that aspirin might have a chemopreventive effect on melanoma incidence.
Researchers found that entry into the ventricle space during surgical resection elevated the risk of leptomeningeal disease in patients with melanoma brain metastases.
Medical and clinical oncologists were more likely than neurosurgeons and radiation oncologists to recommend systemic therapy alone.
Researchers found that entry into the ventricle space during surgical resection elevated the risk of leptomeningeal disease in patients with melanoma brain metastases.
Progression-free survival outcomes were similar with and without spartalizumab.
The objective response rate was 12.5%, and the median progression-free survival was 2.6 months.
The 3-year intracranial progression-free survival rate was 54% in asymptomatic patients and 18.9% in symptomatic patients.